



an Open Access Journal by MDPI

Inflammatory Bowel Diseases: Molecular Mechanisms and Therapies

Guest Editors:

Prof. Ariella Bar-Gil Shitrit

Department of Gastroenterology,
Shaare Zedek Medical Center,
Faculty of Medicine, Hebrew
University, Jerusalem, Israel

Dr. Oren Ledder

The Juliet Keidan Institute of
Paediatric Gastroenterology,
Shaare Zedek Medical Center,
Department of Pediatric
Gastroenterology, Assuta
Hospital Ashdod Faculty of
Medicine, Hebrew University,
Jerusalem, Israel

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editors

Dear Colleagues,

Inflammatory bowel disease (IBD) is a rapidly developing field of gastroenterology and immunology. The purpose of this issue of Biomedicines is to review the current, imminent and future therapeutic armamentarium in IBD from the bench to the bedside. Each review will relate to a different therapeutic class and briefly describe the role of the therapeutic target in the inflammatory cascade, different approaches to manipulating the target, and the resultant drug, with a more in-depth analysis of the efficacy and safety of the drug. The review will include older drugs such as corticosteroids, thiopurines and methotrexate; established biologic therapies such as anti-TNF agents, vedolizumab and ustekinumab; newer small molecules such as tofacitinib; and newer biological agents and small molecules currently in phase 3 testing. Further reviews will relate to other therapies such as antibiotics and microbiome manipulation, nutritional therapy, and stem cells, both in perianal disease and stem cell transplants.

- inflammatory bowel disease
- Crohn's disease
- ulcerative colitis
- therapeutics
- biologic
- microbiome



mdpi.com/si/78676

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI